Результаты поиска

A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers.

This single-center retrospective observational study aimed to identify risk factors for developing denosumab-related osteonecrosis of the jaw (DRONJ) in stage IV solid cancer patients with bone metastases. In total, 123 consecutive patients who had received 120 mg of denosumab every 4 weeks at least twice between July 2014 and October 2018 were included. We surveyed their demographics, medical history, blood test, underlying disease, and intraoral findings. Fourteen patients (11.4%) developed DRONJ within a mean denosumab administration period of 4 months (range: 2-52 months). Univariate analy

Совпадение в полном тексте источника
… The oncologist in charge recommended discontinuation of denosumab, while conservative treatment and regular care were continued. … We recommend that oncologists highlight the importance of maintaining good oral hygiene and recognizing early signs of DRONJ in the context of denosumab treatment for stage IV advanced cancer bone metastases. …

A randomized clinical trial on the effectiveness of an intervention to treat psychological distress and improve quality of life after autologous stem cell transplantation.

Psychological distress contributes to impaired quality of life in hematological cancer patients. Stepped care treatment, in which patients start with the least intensive treatment most likely to work and only receive more intensive interventions if needed, could improve distress. We aimed to evaluate the outcome of stepped care treatment on psychological distress and physical functioning in patients treated with autologous stem cell transplantation for hematological malignancies. In the present study, we performed a randomized clinical trial with two treatment arms: stepped care and care as us

Совпадение в полном тексте источника
… Step 3: Individual face-to-face counseling, psychopharmacological treatment, or referral to other services For patients in step 3, a collaborative care team consisting of a consultant psychiatrist, psychiatric nurse consultant, nurse practitioner (Department of Hematology), hematologist-oncologist, … During regular follow-up visits, emotional support was provided by the hematologist-oncologists and nurses on an ad hoc basis. If patients brought up any problem, hematologist-oncologists or nurses could undertake action and/or refer patients to other services. …

Monoclonal Gammopathy of Undetermined Significance: Follow-up Patterns in the United States and Concordance With Clinical Practice Guidelines.

OBJECTIVE: To determine follow-up practice patterns of US patients with monoclonal gammopathy of undetermined significance (MGUS) and their concordance with 4 clinical practice guidelines. PATIENTS AND METHODS: In a retrospective analysis of adult patients using the OptumLabs Data Warehouse database, we identified those who had an incident diagnosis of MGUS from January 1, 2006, through December 31, 2013, no history or subsequent diagnosis of lymphoplasmacytic malignancy, and at least 2 years of follow-up. RESULTS: A total of 11,676 patients with MGUS were included in the study. During the f

Совпадение в полном тексте источника
… It is possible that many US hematologist-oncologists were unaware of the guidelines because the guidelines were formed by consensus groups from either European or international groups. … Also unknown is the proportion of patients with MGUS in the United States who are followed up by non–hematologist-oncologists. …

Advancing patient-centered cancer care: a systematic review of electronic patient-reported outcome measures.

BackgroundElectronic Patient-Reported Outcome Measures (ePROMs) have emerged as valuable tools in cancer care, facilitating the comprehensive assessment of patients' physical, psychological, and social well-being. This study synthesizes literature on the utilization of ePROMs in oncology, highlighting the diverse array of measurement instruments and questionnaires employed in cancer patient assessments. By comprehensively analyzing existing research, this study provides insights into the landscape of ePROMs, informs future research directions, and aims to optimize patient-centred oncology care

Совпадение в полном тексте источника
… Developed with input from a development cohort of localized prostate cancer patients and an expert panel of urological oncologists, radiation oncologists, survey researchers, and prostate cancer nurses. 8-item Functional Assessment of Cancer Therapy Advanced Prostate Symptom Index (FAPSI) ( 67 ) | Symptoms … patient-reported outcomes (ePROs) into routine cancer care at an academic centre | 16 oncologists with diverse subspecialties and experience in various cancer types | – Customizable ePRO questionnaires—Data visualization tools—Ease of use—Documentation features, including dot phrases for efficient data …

Эффективность и надежность аутологической трансплантации стволовых клеток после химиотерапии при лечении злокачественной лимфомы: метаанализ.

: Автономная трансплантация стволовых клеток (AHSCT) является ценным средством лечения нескольких гематологических заболеваний, особенно в случаях рецидива или рецидива. Автономная трансплантация стволовых клеток (AHSCT) помогает улучшить показатели выживаемости отдельных пациентов, особенно больных с агрессивной лимфомой и множественной миеломой. Исследования показывают, что AHSCT может превзойти альтернативную терапию, но текущие исследования необходимы для совершенствования отбора пациентов. Многие пациенты страдают от продолжительной ремиссии и более высокого качества жизни, что свидетельс

Совпадение в полном тексте источника
… Managing NHL shows complexity as it necessitates a multidisciplinary approach and often close collaboration between oncologists, hematologists, and other healthcare professionals. … Oncologist. 2021;26(2):120–32. 4. Giralt S, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295–308. 5. Stroup DS. Meta-analysis of observational studies in epidemiology. …

A New Deep Learning Algorithm for Detecting Spinal Metastases on Computed Tomography Images.

Study designRetrospective diagnostic study.ObjectiveTo automatically detect osteolytic bone metastasis lesions in the thoracolumbar region using conventional computed tomography (CT) scans, we developed a new deep learning (DL)-based computer-aided detection model.Summary of background dataRadiographic detection of bone metastasis is often difficult, even for orthopedic surgeons and diagnostic radiologists, with a consequent risk for pathologic fracture or spinal cord injury. If we can improve detection rates, we will be able to prevent the deterioration of patients' quality of life at the end

Совпадение в полном тексте источника
… .: 10 years of experience) with consensus by at least one board-certified bone and soft tissue oncologists (S.S. and Y.F.: 24 and 19 years of experience). … Oncologist. 2004;9(suppl 4):14–27. 6. Cole JS, Patchell RA. Metastatic epidural spinal cord compression. Lancet Neurol. 2008;7:459–466. 7. Schiff D, O’Neill BP, Suman VJ. Spinal epidural metastasis as the initial manifestation of malignancy: clinical features and diagnostic approach. …

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review.

There is uncertainty regarding the usefulness of CDK4/6-inhibitor-based therapy for hormone receptor positive (HR+), human epidermal grow factor receptor 2 negative (HER2-), metastatic breast cancer (MBC), when CDK4/6 inhibitor treatment had previously failed. Furthermore, a biomarker for abemaciclib resistance has not been identified. Herein, we reported outcomes for an HR+/HER2- MBC patient diagnosed with multiple myeloma and treated with abemaciclib and exemestane, who had cancer progression after treatment with palbociclib and fulvestrant. Thalidomide was used in conjunction with all treat

Совпадение в полном тексте источника
… This is good news for breast cancer patients, but a challenge for oncologists. … With the approval of these drugs, oncologists were challenged to determine the best treatment for HR+/HER2− MBC patients who had failed previous therapy with a CDK4/6 inhibitor. …

Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series.

BACKGROUND: The purpose of this case series was to further characterize proteasome inhibitor associated chalazia and blepharitis, to investigate outcomes of different management strategies, and to propose a treatment algorithm for eyelid complications in this patient population. METHODS: This retrospective case series included sixteen patients found to have chalazia and/or blepharitis while receiving proteasome inhibitors for plasma cell disorders at Mount Sinai Hospital in New York, NY from January 2010 through January 2017. Main outcomes were complete resolution of eyelid complications and

Совпадение в полном тексте источника
… Upon bortezomib initiation, oncologists may consider an optional ophthalmology referral for a baseline eye exam, patient education on ocular complications of bortezomib, and instruction on preventive eyelid hygiene. … Without knowing the specific incidence and prevalence of bortezomib-associated eyelid complications, this baseline eye screening is up to the oncologist’s discretion and while not imperative, it is encouraged. …

Response Evaluation of Chemotherapy for Lung Cancer.

Assessing response to therapy allows for prospective end point evaluation in clinical trials and serves as a guide to clinicians for making decisions. Recent prospective and randomized trials suggest the development of imaging techniques and introduction of new anti-cancer drugs. However, the revision of methods, or proposal of new methods to evaluate chemotherapeutic response, is not enough. This paper discusses the characteristics of the Response Evaluation Criteria In Solid Tumor (RECIST) version 1.1 suggested in 2009 and used widely by experts. It also contains information about possible d

Совпадение в полном тексте источника
… To supplement this error, about 200 oncologists, immunotherapiests, and regulatory experts shared experiences of immunotherapeutic agents of cancer patients in 2004 to 2005, and concluded with following: the appearance of measurable anti-tumor activity may take longer for immune therapies than for cytotoxic … the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST AJR Am J Roentgenol 2012 198 737 745 22451534 10.2214/AJR.11.7483 PMC3369700 18 Hutson TE Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence Oncologist …

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians).

PurposeTo evaluate differences in baseline parameters including performance status and self-reported symptom burden between geriatric and non-geriatric cancer patients, and to assess the hypothesis that these factors might predispose older patients to incomplete radiotherapy and short survival.Patients and methodsRetrospective comparison of geriatric and non-geriatric patients treated with palliative radiotherapy (age ⩾80 years and ResultsMost patients received radiotherapy for bone metastases, commonly 5-10 fractions. Geriatric patients had significantly less pain at rest and depression. No s

Совпадение в полном тексте источника
… Continuous controversy about radiation oncologists' choice of treatment regimens for bone metastases: should we blame doctors, cancer-related features, or design of previous clinical studies? Radiat Oncol. 2013;8:85. doi: 10.1186/1748-717X-8-85. 27. … Oncologist. 2014;19:275–282. doi: 10.1634/theoncologist.2013-0351. …

Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study.

OBJECTIVE: Despite the guideline-directed therapy, complete absence of nausea was noted only in 33% of breast cancer patients on anthracycline-cyclophosphamide regimen. Hence, we sought to compare the efficacy of aprepitant (APT) versus olanzapine (OLP) in preventing chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients on doxorubicin-cyclophosphamide regimen. PATIENTS AND METHODS: A prospective, open-label, nonrandomized study was conducted at the Department of Oncology. Eighty-three patients completed the study with 43 in the APT group and 40 in OLP group. Data about nau

Dermatologic conditions in women receiving systemic cancer therapy.

As advances in cancer therapies have improved cancer-related survival, novel therapeutics have also introduced a variety of dermatologic toxicities, and an increased number of patients are living with these sequalae. Women with cancer in particular experience a spectrum of dermatologic conditions that affect their skin, hair, nail, and mucosal surfaces. Studies have shown that these toxic effects can significantly affect quality of life and alter a woman's self-image, cultural identity, femininity, sexuality, and mental health. In severe instances, dermatologic toxicities may even disrupt canc

Совпадение в полном тексте источника
… Therefore, timely diagnosis and management of these conditions by dermatologists and oncologists in a multidisciplinary team is crucial for the comprehensive care of women with cancer. … Oncologist. 2012;17(2):291–293. doi: 10.1634/theoncologist.2011-0243. Al-Batran S.E., Meerpohl H.G., von Minckwitz G., Atmaca A., Kleeberg U., Harbeck N. …

Safety of solid oncology drugs in older patients: a narrative review.

The older population represents ∼50%-60% of the population of newly diagnosed patients with cancer. Due to physiological and pathological aging and the increased presence of comorbidities and frailty factors, this population is at higher risk of serious toxicity from anticancer drugs and, consequently, often under-treated. Despite the complexity of these treatments, a good knowledge of the pharmacology of anticancer drugs and potentially risky situations can limit the emergence of potentially lethal toxicities in this population. This review focuses on optimizing systemic oncology treatments f

Cardiometabolic Comorbidities in Cancer Survivors: JACC: CardioOncology State-of-the-Art Review.

There are nearly 17 million cancer survivors in the United States, including those who are currently receiving cancer therapy with curative intent and expected to be long-term survivors, as well as those with chronic cancers such as metastatic disease or chronic lymphocytic leukemia, who will receive cancer therapy for many years. Current clinical practice guidelines focus on lifestyle interventions, such as exercise and healthy eating habits, but generally do not address management strategies for clinicians or strategies to increase adherence to medications. We discuss 3 cardiometabolic comor

Совпадение в полном тексте источника
… Medical oncologists often served as the cancer patient’s primary care provider. 43 , 44 Surgeons and radiation oncologists often felt more comfortable managing noncancer problems for their cancer survivors than primary care providers (PCPs), as the latter group became increasingly removed from active … An automated electronic health system messaging algorithm then sends alerts for abnormal weekly average pressures to the cancer survivors’ primary care team, with copies to the patient and the oncologist. …

Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.

Tyrosine kinase inhibitors (TKIs) are anti-cancer drugs that target tyrosine kinases, enzymes that are involved in multiple cellular processes. Currently, multiple oral TKIs have been introduced in the treatment of solid tumours, all administered in a fixed dose, although large interpatient pharmacokinetic (PK) variability is described. For imatinib, sunitinib and pazopanib exposure-treatment outcome (efficacy and toxicity) relationships have been established and therapeutic windows have been defined, therefore dose optimization based on the measured blood concentration, called therapeutic dru

Assessment of kidney transplant suitability for patients with prior cancers: is it time for a rethink?

Kidney transplant recipients have up to a 100-fold greater risk of incident cancer compared with the age/sex-matched general population, attributed largely to chronic immunosuppression. In patients with a prior history of treated cancers, the type, stage and the potential for cancer recurrence post-transplant of prior cancers are important factors when determining transplant suitability. Consequently, one of the predicaments facing transplant clinicians is to determine whether patients with prior cancers are eligible for transplantation, balancing between the accelerated risk of death on dialy

Care of cancer patients at the end of life in a German university hospital: A retrospective observational study from 2014.

BackgroundCancer care including aggressive treatment procedures during the last phase of life in patients with incurable cancer has increasingly come under scrutiny, while integrating specialist palliative care at an early stage is regarded as indication for high quality end-of-life patient care.AimTo describe the demographic and clinical characteristics and the medical care provided at the end of life of cancer patients who died in a German university hospital.MethodsRetrospective cross-sectional study on the basis of anonymized hospital data for cancer patients who died in the Munich Univers

Совпадение в полном тексте источника
… Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist. 2006;11(10): 1095–9. 10.1634/theoncologist.11-10-1095 33. Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS. … : a survey of medical oncologists and midlevel Providers at a comprehensive cancer center. Cancer. 2009;115(9): 2013–21. 10.1002/cncr.24206 65. Klinger CA, Howell D, Zakus D, Deber RB. …

Current Advancements in the Diagnosis and Treatment of Metastatic Spinal Cord Compression and Its Postintervention Care: A Comprehensive Review.

Malignant spinal cord compression (MSCC) is a serious oncological emergency that can result in neurological impairment and significant pain. It is associated with high morbidity, mortality, and a decrease in quality of life. This review reviews the current literature concerning diagnosis, guidelines, timely intervention, and management options in oncology patients with MSCC. A literature search of PubMed using relevant keywords and MeSH terms yielded 604 articles. Of these, 31 studies met the predefined inclusion criteria and were selected for detailed data extraction and synthesis into a narr

Совпадение в полном тексте источника
… Post-intervention care A Multidisciplinary Recovery Model Creating a personalized treatment plan leads to a faster and more positive outcome, achieved through a multidisciplinary approach involving oncologists, radiation therapists, neurosurgeons, physiotherapists, and pain specialists [ 15 ]. … A multidisciplinary approach is essential to the correct identification of the symptomatology of MSCC patients, together with collaboration among oncologists, surgeons, radiation therapists, and rehabilitation specialists, and a careful selection of the available treatments depending on the individual …

Extracorporeal membrane oxygenation in critically ill patients with active hematologic and non-hematologic malignancy: a literature review.

Combined progress in oncology and critical care medicine has led to new aspirations and discussions in advanced life support modalities in the intensive care unit. Over the last decade, extracorporeal membrane oxygenation, previously considered unsuitable for oncologic patients, has become increasingly popular, with more diverse applications. Nevertheless, mortality remains high in critically ill cancer patients, and eligibility for extracorporeal membrane oxygenation can be extremely challenging. This scenario is even more difficult due to the uncertain prognosis regarding the underlying mali

Совпадение в полном тексте источника
… Studies with larger sample sizes and cohorts are needed to create well-defined guidelines to guarantee that intensivists and hemato-oncologists may better approach the management of cancer patients with a possible ECMO indication. … Oncologist. (2014) 19:985–9. doi: 10.1634/theoncologist.2014-0025, PMID: 41. Allain G, Hajj-Chahine J, Lacroix C, Jayle C. Primary cardiac lymphoma complicated by cardiogenic shock: successful treatment with chemotherapy delivered under extracorporeal membrane oxygenation support. …

Progression of Femoral Osteolytic Metastases after Intramedullary Nailing and Subsequent Salvage Techniques.

Intramedullary nailing insertion from the proximal-to-distal femur is frequently performed for impending and complete pathological femur fractures due to osteolytic metastases. After nailing through cancer-laden bone, residual chemotherapy- and/or radiation-resistant tumor may progress. Progression of osteolysis risks future nail failure or pathological fractures. This study assesses the incidence of cancer progression following intramedullary nailing in a femur-only cohort and describes a percutaneous rod-retaining salvage technique. A single-institution, retrospective study was conducted to

Совпадение в полном тексте источника
… Surgical intervention was decided by a multidisciplinary team of medical oncologists, radiologists, and orthopedic oncologists in line with shared decision making with the patient. Common indications included severe mechanical axial loading pain (nonambulatory) and completed pathologic fracture. … All patients who underwent percutaneous salvage were discussed by an interdisciplinary team of interventional radiologists and orthopedic oncologists and deemed to be at imminent risk of catastrophic nail failure due to cancer progression in the femur. …